Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer

ClinicalTrials.gov ID: NCT00034827

Public ClinicalTrials.gov record NCT00034827. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung Cancer, Breast Cancer, Colon Cancer, or Pancreatic Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

CI-1040 is an experimental drug that is being tested in patients who have advanced colorectal and lung cancer who failed no more than one prior chemotherapy regimen, breast cancer who have failed no more than 2 prior regimens and in patients with pancreatic cancer who have received no prior chemotherapy. CI-1040 is taken orally twice daily with meals. Patients are required to have blood tests periodically while receiving treatment and will be monitored closely throughout the trial for possible side effects and for response.

Study identification

NCT ID
NCT00034827
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
172 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2001
Primary completion
Not listed
Completion
Apr 30, 2003
Last update posted
May 3, 2007

2002 – 2003

United States locations

U.S. sites
30
U.S. states
7
U.S. cities
26
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama 35205
Pfizer Investigational Site Birmingham Alabama 35233
Pfizer Investigational Site Blendora California 91740
Pfizer Investigational Site Glendale California 91204
Pfizer Investigational Site Huntington Beach California 92648
Pfizer Investigational Site Long Beach California 90813
Pfizer Investigational Site Los Alamitos California 90720
Pfizer Investigational Site Los Angeles California 90048
Pfizer Investigational Site Los Angeles California 90095
Pfizer Investigational Site Mission Hills California 91345
Pfizer Investigational Site Northridge California 91328
Pfizer Investigational Site Oxnard California 93030
Pfizer Investigational Site Pasadena California 91105
Pfizer Investigational Site Pomona California 91767
Pfizer Investigational Site Rancho Cucamonga California 91730
Pfizer Investigational Site Redondo Beach California 90277
Pfizer Investigational Site Santa Monica California 90404
Pfizer Investigational Site Torrance California 90505
Pfizer Investigational Site Ventura California 93003
Pfizer Investigational Site West Covina California 91790
Pfizer Investigational Site Atlanta Georgia 30342
Pfizer Investigational Site Decatur Georgia 30033
Pfizer Investigational Site Macon Georgia 30342
Pfizer Investigational Site Crestview Hills Kentucky 41017
Pfizer Investigational Site Detroit Michigan 48201
Pfizer Investigational Site Rochester Minnesota 55905
Pfizer Investigational Site Cincinnait Ohio 45236
Pfizer Investigational Site Cincinnati Ohio 45219
Pfizer Investigational Site Cincinnati Ohio 45230
Pfizer Investigational Site Cincinnati Ohio 45242

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00034827, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 3, 2007 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00034827 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →